The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity.
Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.